Hook & thesis
Huntsman (HUN) continues to claw its way back: revenue is rising, margin drivers in Polyurethanes and Advanced Materials are producing meaningful adjusted EBITDA gains, and the company is on track for a planned merger with Olin that could unlock further strategic optionality. The market punished the shares after an adjusted EPS miss in Q3, but the sell-off has left the stock trading at a valuation that looks compelling relative to the recent operational momentum.
My short-term tactical view is constructive: buy at $9.60 with a stop at $8.50 and a target of $12.00, horizon mid term (45 trading days). That setup captures a recovery narrative already underway while capping downside around the $8.50 technical/structural support area and leaving room for a re-rating as the merger progresses.
Business overview and why investors should care
Huntsman manufactures differentiated organic chemicals in three main segments: Polyurethanes, Performance Products and Advanced Materials. These businesses sell into industrial and consumer supply chains where pricing, volumes and raw material spreads drive profitability. Polyurethanes provides MDI, polyols and related inputs to foam and insulation markets; Performance Products supplies amines and surfactants; Advanced Materials is the epoxy and specialty resin franchise that participates in higher-value applications.
Investors should care because Huntsman sits at the intersection of cyclical industrial demand and specialty-chemical margin expansion. When product prices and volumes recover, Huntsman benefits through strong segment-level EBITDA leverage. Management has been increasingly vocal about operational improvements and consolidation optionality, and the announced merger with Olin creates a visible corporate catalyst that could compress perceived execution risk.
What the numbers say
Recent results and market metrics give the recovery thesis some teeth. Q3 revenue was $1.717 billion, which is up 17.6% year-over-year and beat consensus by about 7.2%. The company reported adjusted EPS of $0.04, missing the $0.07 estimate, but that headline miss masks better unit-level performance: adjusted EBITDA in Polyurethanes rose 56% and Advanced Materials jumped 41% year-over-year.
On valuation, the share price is modest. Market capitalization is roughly $1.69 billion and enterprise value sits at about $3.34 billion. Price-to-book is ~0.62 and EV/EBITDA is ~10.6, while the trailing P/E shows a negative due to prior losses (reported EPS -$0.99). The company carries a dividend yielding roughly 3.7% and pays $0.0875 per share quarterly; that yield is a modest income cushion for total-return oriented traders.
| Metric | Value |
|---|---|
| Current price | $9.62 (market) |
| Market cap | $1.69B |
| Enterprise value | $3.34B |
| EV / EBITDA | 10.6 |
| Price / Book | ~0.62 |
| Q3 Revenue | $1.717B (up 17.6% YoY) |
| Q3 adjusted EPS | $0.04 (missed $0.07 est.) |
Technical and sentiment backdrop
Technically, HUN looks constructive. The 10-day SMA sits at $9.51, while the 20- and 50-day SMAs are $9.00 and $9.01, respectively, leaving the current price just above near-term trend lines. Momentum indicators favor buyers: RSI near 57.5 and a bullish MACD histogram suggest room for further upside without being overbought. Average daily volume runs around ~3.1M shares, versus today’s volume near 1.4M, meaning the trade should have liquidity if activity picks up.
Short interest has come down materially from earlier peaks, with the latest settlement showing ~11.0M shares short (days-to-cover ~3.86). Short-volume data indicates persistent short activity in recent sessions, which could add directional volatility if sentiment shifts—either amplifying a squeeze or accentuating downside on negative headlines.
Valuation framing
It’s rare to find a diversified specialty chemical name trading below 1.0x book with positive top-line momentum and double-digit EV/EBITDA in the low teens. At a market cap under $1.7B and P/B ~0.62, the market is still applying a sizable discount for execution risk and cyclical exposure. The EV/EBITDA of ~10.6 is reasonable given the segment mix and the potential for margin recovery in polyurethane fundamentals and epoxy/resin demand.
Compare this to historical levels: HUN’s 52-week high was $16.09 on 06/15/2026 and the 52-week low was $7.74 on 11/07/2025. The current price sits closer to the lower end while a recovery toward $12 would be only ~25% below the 52-week high and represent a re-rating consistent with normalized margins and partial multiple expansion.
Catalysts
- Merger progress with Olin - the companies expect a closing in Q1 2027; completion or favorable deal developments are likely to reduce uncertainty and could boost the share price.
- Continued margin improvement in Polyurethanes and Advanced Materials - recent adjusted EBITDA growth (+56% and +41%) shows operating leverage that can accelerate EPS improvement.
- Improving pricing/volumes across end markets - if industrial demand holds or improves, revenue and EBITDA should continue to expand from the current $1.717B quarterly run-rate.
- Short-covering episodes - elevated short-volume in recent sessions creates the potential for rapid upside if a positive catalyst triggers covering.
Trade plan (actionable)
Direction: Long
Entry: $9.60
Stop loss: $8.50
Target: $12.00
Horizon: mid term (45 trading days)
Rationale: Entering at $9.60 places you just above the short-term SMAs, capturing the ongoing operational recovery while limiting downside to the $8.50 area just above the 52-week low buffer and a round-number support zone. The $12.00 target is reachable if Q4 operational cadence keeps improving and the market starts to price in the Olin merger closer to completion—or if a short-covering squeeze accelerates price action. The 45 trading day horizon balances catalyst timing (merger progress and quarter-to-quarter operational updates) against market noise.
Risks and counterarguments
- Merger risk: The planned Olin transaction is a binary event. Any delay, adverse regulatory feedback, or renegotiation could reintroduce uncertainty and weigh on the shares.
- Earnings and cash flow cadence: The company reported a Q3 adjusted EPS miss ($0.04 vs $0.07 est.) and negative trailing EPS shows Huntsman’s earnings can still be volatile. Free cash flow was negative at about -$85M, which constrains flexibility if markets worsen.
- Commodity and raw material volatility: Input cost swings can rapidly compress spreads in polyurethane and resin businesses; a reversal in price dynamics could quickly erode the recent EBITDA gains.
- Macro slowdown risk: A softening in industrial demand or slower end-market growth would reduce volumes and pricing power, reversing the recovery story.
- Sentiment/short pressure: Elevated short-volume indicates the stock can move quickly; if negatives surface, downside can be sharp as short sellers pile in.
Counterargument: A conservative case says the revenue beat in Q3 masks ongoing operational and cash generation problems—negative trailing EPS and negative free cash flow highlight that adjusted EBITDA improvements don’t yet fully translate into durable earnings quality. If the company’s organic cash conversion stalls or merger benefits are smaller than anticipated, the valuation discount may persist and push the stock back toward its low end.
What would change my mind
I would reduce conviction or exit the trade if any of the following occur: (1) the Olin merger faces material regulatory difficulty or is delayed beyond Q1 2027, (2) Huntsman reports another quarter of weak cash flow or larger-than-expected restructuring/one-time charges that impair liquidity, or (3) commodity-driven spreads deteriorate sharply and the company signals sustained volume weakness. Conversely, I would add to the position if management provides stronger-than-expected free cash flow guidance, announces concrete synergies tied to the Olin deal, or reports sequential margin expansion beyond current adjusted EBITDA trends.
Conclusion
Huntsman presents a pragmatic swing trade: revenue and segment-level EBITDA are improving, the balance sheet metrics and dividend provide a floor, and the Olin merger creates a visible timeline for de-risking. The company’s market cap near $1.7B, P/B around 0.62 and EV/EBITDA ~10.6 are consistent with a value setup where upside is more likely than further multiple compression if the operational recovery continues.
My recommendation: buy at $9.60, stop $8.50, target $12.00, over a mid-term window of 45 trading days—monitor merger developments, quarterly cash flow conversion and raw material spreads closely. If those metrics move in the right direction, the valuation is likely to re-rate; if they disappoint, tighten stops or exit.
Trade idea by Sofia Navarro - practical, number-first approach to a chemicals recovery play.